New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
14:43 EDTAMGN, ILMNIllumina February volatility up, shares at record high on agreement with Amgen
Illumina (ILMN) February call option implied volatility is at 40, March is at 36, June is at 35; compared to its 26-week average of 35 according to Track Data, suggesting large near term price movement on an agreement with Amgen (AMGN) to develop oncology companion diagnostic test.
News For ILMN;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:50 EDTILMNNeogen expands relationship with Illumina
Neogen (NEOG) announced that it has signed an agreement to expand its relationship with Illumina (ILMN). Under the agreement, Illumina will market and sell arrays with Neogen's custom SNP content, built on Illumina Infinium BeadArray technology, to the global agrigenomics community.
July 2, 2015
07:48 EDTILMNFluidigm, Illumina single cell opportunities compelling, says Leerink
Subscribe for More Information
July 1, 2015
09:35 EDTILMNIllumina price target raised to $300 from $264 at Cowen
Subscribe for More Information
June 30, 2015
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 25, 2015
09:27 EDTILMNLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools and Diagnostics Dan Leonard, along with Dr. Paul Robson and Dr. Peter Kuhn, discuss the demand for Fluidigm's single cell prep products, including the impact to Biomark and the utility of CyTOF on an Analyst/Industry conference call to be held on July 1 at 2 pm.
09:21 EDTILMNBioMed Realty leases build-to-suit laboratory in Cambridge to Illumina
BioMed Realty (BMR) announced that Illumina ILMN) has signed a 20-year lease for a 155,000 square foot new and innovative scientific research building in Cambridge, England. BioMed Realty acquired the land for the project from The Welding Institute under a long term ground lease, enlarging BioMed Realty's Granta Park campus in Cambridge, England.
June 24, 2015
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use